Papers in the journal Haematologica (Page 2)

#21

JOURNAL ARTICLE

A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma.

Josefine Krüger, Matthias Obenaus, Igor Wolfgang Blau, Dana Hoser, Martin Vaegler, Hana Rauschenbach, Ioannis Anagnostopoulos, Korinna Jöhrens, Vivian Scheuplein, Elisa Kieback, Judith Böhme, Ann-Christin Von Brünneck, Jan Krönke, Antonia Busse, Gerald Willimsky, Thomas Blankenstein, Antonio Pezzutto, Ulrich Keller, Axel Nogai

Not available.

39279443

September 12, 2024: Haematologica

#22

JOURNAL ARTICLE

Help or hindrance? Rituximab maintenance and COVID.

Ariela Noy

Not available.

39279441

September 12, 2024: Haematologica

#23

JOURNAL ARTICLE

Adopting the new iStopMM-based criteria for light-chain monoclonal gammopathy of undetermined significance: an ongoing debate.

Dor Shpitzer, Yael C Cohen, Tamir Shragai, Guy Melamed, Anat Reiner-Benaim, Irit Avivi

Not available.

39279433

September 12, 2024: Haematologica

#24

JOURNAL ARTICLE

Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study.

Mariana Nassif Kerbauy, Fernanda Agostini Rocha, Leonardo Javier Arcuri, Priscila Silva Cunegundes, Lucila Nassif Kerbauy, Clarisse Martins Machado, Andreza Alice Feitosa Ribeiro, Pinaki P Banerjee, Luciana Cavalheiro Marti, Nelson Hamerschlak

Post-transplant cyclophosphamide has contributed to the success of haploidentical hematopoietic stem cell transplantation (HSCT) and is also been used in transplantation from matched donors. However, limited data on the immune reconstitution after this type of immunosuppression is available. We aimed to evaluate immune reconstitution after HSCT from unrelated donors, comparing anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy). Consecutive patients undergoing HSCT from unrelated donors and receiving either ATG or PTCy were prospectively included...

39279428

September 12, 2024: Haematologica

#25

JOURNAL ARTICLE

Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen.

Christina Peters, Angela Bruno, Carmelo Rizzari, Alessandra Brescianini, Arend Von Stackelberg, Christin Linderkamp, Yi Zeng, Gerhard Zugmaier, Franco Locatelli

Not available.

39234873

September 5, 2024: Haematologica

#26

JOURNAL ARTICLE

Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.

Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, Siddhartha Ganguly, Praveen Ramakrishnan Geethakumari, Sanghee Hong, Adriana Malone, Hemant Murthy, Attaphol Pawarode, Alejandro R Sica, Melhem Solh, Celalettin Ustun, Mazyar Shadman, Craig S Sauter, Mehdi Hamadani, Alex F Herrera, Catherine J Lee

No abstract text is available yet for this article.

39234871

September 5, 2024: Haematologica

#27

JOURNAL ARTICLE

Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis.

Nicola S Curry, Jeries Abu-Hanna, Gael B Morrow, Robin Choudhury, Michael Laffan

Trauma induced coagulopathy (TIC) describes a complex set of coagulation changes affecting severely injured patients. The thrombomodulin-protein C axis is believed to be central to the evolution of TIC. Soluble thrombomodulin (sTM) levels are elevated after injury. Our objectives were to explore whether sTM (at concentrations found in patients after injury) plays an important role in TIC, and specifically to evaluate the effect of sTM and activated protein C (APC) on thrombin generation (TG) and clot lysis time (CLT)...

39234869

September 5, 2024: Haematologica

#28

JOURNAL ARTICLE

Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.

Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai Hu, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Zhenguang Wang, Rong Zhu, Lei Yang, Dan Song, Yuqin Song, Jun Zhu

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R/R DLBCL in a global phase 2 LOTIS-2 study. In the China bridging pivotal phase 2 OL-ADCT-402-001 study, eligible patients aged ≥18 years with R/R DLBCL who had failed ≥ 2 lines of systemic therapies were enrolled and treated with Lonca every 3 week with 150 μg/kg for 2 cycles; then 75 μg/kg for subsequent cycles (up to 1 year)...

39234866

September 5, 2024: Haematologica

#29

JOURNAL ARTICLE

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting.

Gaia Ciolli, Matteo Piccini, Francesco Mannelli, Giacomo Gianfaldoni, Barbara Scappini, Laura Fasano, Francesca Crupi, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Fiorenza I Vanderwert, Paola Guglielmelli, Alessandro M Vannucchi

Not available.

39234864

September 5, 2024: Haematologica

#30

JOURNAL ARTICLE

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.

Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, Michelle Okwali, Irem Isgor, Philip C Caron, Zachary Epstein-Peterson, Paola Ghione, Paul Hamlin, Jennifer Lue, Steven M Horwitz, Andrew M Intlekofer, William Johnson, Anita Kumar, Alison Moskowitz, Ariela Noy, Colette Owens, Lia M Palomba, Pallawi Torka, Pallavi Galera, Andrew D Zelenetz, Gilles Salles, Lorenzo Falchi

The combination of rituximab and lenalidomide (R-len) stands as an established treatment for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, the reproducibility of clinical trial results in routine clinical practice is unknown. To address this gap in knowledge, we reviewed our experience with patients diagnosed with R/R follicular lymphoma (FL) or marginal zone lymphoma (MZL) treated with this combination. Eighty-four patients underwent treatment with R-len, 69 (82%) affected by FL and 15 (18%) by MZL...

39234863

September 5, 2024: Haematologica

#31

JOURNAL ARTICLE

Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.

Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D Smith

This multicenter, open-label, phase 1b study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naive (TN) and relapsed or refractory (R/R) mantle cell lymphoma (MCL). Patients received acalabrutinib from cycle 1 until disease progression or treatment discontinuation, bendamustine on days 1 and 2 of each cycle for up to 6 cycles, and rituximab on day 1 of each cycle for 6 cycles, continuing every other cycle from cycle 8 for 12 additional doses (TN cohort)...

39234862

September 5, 2024: Haematologica

#32

JOURNAL ARTICLE

Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.

Ross T Salvaris, Benjamin M Allanson, Graham Collins, Chan Cheah

Recent updates have detailed how patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) may be better risk stratified using prognostic scoring systems. Most patients with NLPHL present with early-stage disease and have an indolent disease course. To reflect these differences from classic Hodgkin lymphoma, nomenclature has been updated to recognise nodular lymphocyte predominant B-cell lymphoma as an alternative to NLPHL. The Global NLPHL One Working Group have published their pivotal dataset in 2024 which challenges the prognostic significance of variant immunoarchitectural (IAP) patterns and proposes a new prognostic scoring system...

39234861

September 5, 2024: Haematologica

#33

JOURNAL ARTICLE

Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with RUNX1::RUNX1T1 .

Shota Kato, Shin-Ichi Tsujimoto, Jun Matsubayashi, Shotaro Iwamoto, Hidefumi Hiramatsu, Yusuke Okuno, Tatsuya Kamitori, Kentaro Ohki, Takao Deguchi, Nobutaka Kiyokawa, Motohiro Kato, Junko Takita, Shiro Tanaka, Souichi Adachi, Daisuke Tomizawa, Norio Shiba

Not available.

39234860

September 5, 2024: Haematologica

#34

JOURNAL ARTICLE

The real world of acute lymphoblastic leukemia.

Mark R Litzow

Not available.

39234859

September 5, 2024: Haematologica

#35

JOURNAL ARTICLE

BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1.

Valeria Tosello, Ludovica Di Martino, Adonia E Papathanassiu, Silvia Dalla Santa, Marco Pizzi, Lara Mussolin, Jingjing Liu, Pieter Van Vlierberghe, Erich Piovan

High levels of branched-chain amino acid (BCAA) transaminase 1 (BCAT1) have been associated with tumor aggressiveness and drug resistance in several cancer types. Nevertheless, the mechanistic role of BCAT1 in T-cell acute lymphoblastic leukemia (T-ALL) remains uncertain. We provide evidence that Bcat1 was over-expressed following NOTCH1-induced transformation of leukemic progenitors and that NOTCH1 directly controlled BCAT1 expression by binding to a BCAT1 promoter. Further, using a NOTCH1 gain-of-function retroviral model of T-ALL, mouse cells genetically deficient for Bcat1 showed defects in developing leukemia...

39234857

September 5, 2024: Haematologica

#36

JOURNAL ARTICLE

AURKA targeting: a NEAT approach to halt myeloma.

Antonio Giovanni Solimando, Cirino Botta

Not available.

39219507

August 29, 2024: Haematologica

#37

JOURNAL ARTICLE

Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study.

Christa L Meyer, Theresa H M Keegan, Ann Brunson, Jeffery J Auletta, Lindsay M Morton, Ted Wun, Sara J Schonfeld, Bryan Valcarcel, Renata Abrahão, Rafeek A Yusuf, Lori Muffly

Acute myeloid leukemia (AML) often requires allogeneic hematopoietic cell transplantation (alloHCT) for cure, but historically alloHCT has been strikingly underutilized. Reasons for this remain uncertain at the population level. We examined alloHCT utilization over time and explored associations between demographic/healthcare factors and use of alloHCT by age group (AYA 15-39y, adult 40-64y, older adult 65-79y) using a linked dataset merging the Center for International Blood and Marrow Transplant Research, California Cancer Registry, and California Patient Discharge Database...

39219504

August 29, 2024: Haematologica

#38

JOURNAL ARTICLE

T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.

Edith Willscher, Christoph Schultheiß, Lisa Paschold, Franziska Lea Schümann, Paul Schmidt-Barbo, Benjamin Thiele, Marcus Bauer, Claudia Wickenhauser, Thomas Weber, Mascha Binder

While T cell lymphomas are classified as mature neoplasms, emerging evidence indicates that malignant transformation may occur at an earlier stage of T cell maturation. In this study, we determined clonal architectures in a broad range of T cell lymphomas. Our multidimensional profiling indicates that a large part of these lymphomas in fact emerge from an immature lymphoid T cell precursor at a maturation stage prior to V(D)J rearrangement that undergoes branching evolution. Consequently, at single cell resolution we observed considerable clonal tiding under selective therapeutic pressure...

39219501

August 29, 2024: Haematologica

#39

JOURNAL ARTICLE

Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis.

Julien Rossignol, Sophie Georgin-Lavialle, Danielle Canioni, Omer Beganovic, Chantal Brouzes, Olivier Fain, Maël Heiblig, Clément Gourguechon, Philippe Guilpain, Cristina Bulai-Livideanu, Stéphane Barete, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Catharina Chatain, Ghandi Damaj, Thomas Ballul, Celine Greco, Laura Polivka, Laurent Frenzel, Cécile Meni, Hassiba Bouktit, Dina Benabou, Clotilde Devin, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Thierry Jo Molina, Julie Bruneau, Rose-Marie Javier, Fabien Pelletier, Florence Castelain, Frederique Retornaz, Quentin Cabrera, Patricia Zunic, Marie Pierre Gourin, Ewa Wierzbicka-Hainaut, Jean François Viallard, Christian Lavigne, Cyrille Hoarau, Isabelle Durieu, Sophie Dimicoli-Salazar, Jose Miguel Torregrosa-Diaz, Audrey Duval, Nicolas Garcelon, Jeremie Lespinasse, Angèle Soria, Yannick Chantran, Michel Arock, Christine Bodemer, Olivier Lortholary, Vahid Asnafi, Olivier Hermine, Ludovic Lhermitte

Not available.

39219498

August 29, 2024: Haematologica

#40

JOURNAL ARTICLE

Entities versus diseases: Myers et al . propose distinct aspects of adult T-cell lymphoma/leukemia.

Stefano A Pileri

Not available.

39219497

August 29, 2024: Haematologica